FDA reviews clinical trials for CT laser mammography

Article

The Food and Drug Administration is reviewing a progress report from Imaging Diagnostic Systems about an optical method of diagnostic imaging to find suspicious growths that illuminates the breast with near-infrared light instead of traditional breast

The Food and Drug Administration is reviewing a progress report from Imaging Diagnostic Systems about an optical method of diagnostic imaging to find suspicious growths that illuminates the breast with near-infrared light instead of traditional breast compression x-ray.

For six years, Plantation, FL-based Imaging Diagnostic Systems (IMDS) has been developing computed tomography laser mammography. In CTLM, contiguous 4-mm-slice views are reconstructed into a near-three-dimensional view of the breast. Digital display allows computer enhancements to clarify questionable areas within the imaged area.

Because seven of eight breast biopsies come back with normal results, CTLM’s ability to capture a better picture of breasts will cut down the number of women needlessly worrying about cancer and the number of unnecessary costly biopsies, said Richard Grable, CEO of IMDS.

CTLM will help physicians decide whether to recommend further clinical work-ups, he said.

The CTLM scanner sees a tissue change in areas where mammography has revealed calcifications. In imaging the breast, there is a particular size and distribution of calcifications that is highly suggestive of cancer growing, Grable said.

In IMDS’ trials, the patient is given a traditional mammogram first. Then the CTLM acquires the data and the image is reconstructed. The resulting image is compared to the original mammogram, Grable said.

“We are still learning how the CTLM compares to traditional mammography,” Grable said.

This type of scanner can also work with contrast agents traditionally used in MR, CT, and x-ray. CTLM can identify contrast agent indocyanine green (ICG). The lesion’s blood supply absorbs the dye, which is illuminated by the laser scanner.

In the future, ICG may serve as a foundation for fluorescent tags fixed to a group of nascent cancer cells. CTLM will pick up the tags so clinicians can see suspicious areas, Grable said.

With this development, clinicians could detect cancer much earlier. CTLM will help do this with clearer imaging, Grable said. Right now, a woman can detect a 2-cm lump by doing a breast self-exam, while a clinician using traditional mammography can find a 1-cm lump.

A tag that identifies suspicious cells has been the dream of medicine for a long time, Grable said.

Clinical trials were held at Nassau County Medical Center in New York and the University of Virginia’s Breast Center.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.